Regeneron director exercises options and sells shares
REGENERON PHARMACEUTICALS, INC. director Huda Y. Zoghbi reported an option exercise-and-sale on August 10, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
REGENERON PHARMACEUTICALS, INC. director Huda Y. Zoghbi reported an option exercise-and-sale on August 10, 2026. She exercised 800 Non‑Qualified Stock Options for 800 shares of Common Stock at an exercise price of $376.6900 per share, fully exhausting this option grant, and then sold the 800 acquired shares. All transactions were made under a Rule 10b5‑1(c) trading plan adopted on November 20, 2025.
Insider Trade Summary 10b5-1
Exercise and Sale: 800 shares ($339K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Zoghbi Huda Y
Role
Director
Sold
800 shs ($640K)
Approx. gross sale proceeds
$640K
Approx. exercise cost
$301K
Approx. pre-tax spread
$339K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-Qualified Stock Option (right to buy) F1, F2 | 800 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 800 | $376.69 | $301K |
| Sale | Common Stock F1 | 800 | $800.00 | $640K |
Holdings After Transaction:
Non-Qualified Stock Option (right to buy) — 0 contracts (Direct);
Common Stock — 1,703 shares (Direct)
Footnotes (2)
- F1. Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025.
- F2. The stock option vested in three equal annual installments, commencing one year after the date of grant.
Key Figures
Options exercised: 800 shares
Exercise price: $376.6900 per share
Shares sold: 800 shares
+3 more
6 metrics
Options exercised
800 shares
Non-Qualified Stock Options exercised into Common Stock on August 10, 2026
Exercise price
$376.6900 per share
Exercise price of Non-Qualified Stock Option grant
Shares sold
800 shares
Common Stock sale on August 10, 2026 following option exercise
Options remaining from grant
0.0000
Non-Qualified Stock Option position after the reported exercise
Option expiration date
2027-01-03
Expiration date of the exercised Non-Qualified Stock Option grant
10b5-1 plan adoption date
November 20, 2025
Rule 10b5-1(c) trading plan governing the reported transactions
Key Terms
Non-Qualified Stock Option, Rule 10b5-1(c), Exercise or conversion of derivative security
3 terms
Non-Qualified Stock Option financial
"Security titled "Non-Qualified Stock Option (right to buy)" was exercised for 800 shares"
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
Rule 10b5-1(c) regulatory
"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)"
Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.
Exercise or conversion of derivative security financial
"Transaction code M described as "Exercise or conversion of derivative security""
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did REGN director Huda Y. Zoghbi report on August 10, 2026?
On August 10, 2026, director Huda Y. Zoghbi exercised 800 stock options for 800 shares of Regeneron Common Stock and sold 800 shares in a related transaction reported on Form 4.
At what price were Huda Y. Zoghbi’s REGN options exercised on August 10, 2026?
The Non‑Qualified Stock Options were exercised at an exercise price of $376.6900 per share. This exercise converted 800 options into 800 shares of Common Stock before a same‑day sale of those shares was reported.
Were Huda Y. Zoghbi’s August 2026 REGN trades made under a Rule 10b5-1 plan?
Yes. The filing states the disposition and acquisition were made pursuant to a Rule 10b5‑1(c) trading plan adopted on November 20, 2025, indicating the transactions were pre‑planned.
What happened to Huda Y. Zoghbi’s Regeneron stock option grant after the August 2026 exercise?
After exercising 800 Non‑Qualified Stock Options, the filing shows 0.0000 options remaining from that grant. The option, which vested in three equal annual installments, had an expiration date of January 3, 2027.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates